Molecular diagnostics for monitoring and predicting therapeutic effect in cancer

References

• Cho WC. Conquering cancer through discovery research. IUBMB Life62(9), 655–659 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC. Cancer biomarkers (an overview). In: Methods of Cancer Diagnosis, Therapy and Prognosis (Volume 7). Hayat MA (Ed.). Springer, Berlin, Germany 21–40 (2010).
   Google Scholar
• Goto Y, Koyanagi K, Narita N et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J. Invest. Dermatol.130(1), 221–229 (2010).
   PubMedGoogle Scholar
• Wang H, Yan H, Fu A et al. TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation. PLoS ONE5(8), e12051 (2010).
   Google Scholar
• de Jong MC, Pramana J, van der Wal JE et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin. Cancer Res.16(21), 5329–5338 (2010).
   PubMed Web of Science ®Google Scholar
• Daskalaki A, Agelaki S, Perraki M et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br. J. Cancer101(4), 589–597 (2009).
   PubMedGoogle Scholar
• Xenidis N, Ignatiadis M, Apostolaki S et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol.27(13), 2177–2184 (2009).
   PubMed Web of Science ®Google Scholar
• Bass MB, Sherman SI, Schlumberger MJ et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab.95(11), 5018–5027 (2010).
   PubMed Web of Science ®Google Scholar
• Koyanagi K, O’Day SJ, Boasberg P et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin. Cancer Res.16(8), 2402–2408 (2010).
   PubMed Web of Science ®Google Scholar
• Zuo Z, Jones D, Yao H et al. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod. Pathol.23(11), 1524–1534 (2010).
   PubMedGoogle Scholar
• Tabchy A, Valero V, Vidaurre T et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res.16(21) 5351–5361 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol.42(8), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs in cancer – from research to therapy. Biochim. Biophys. Acta1805(2), 209–217 (2010).
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Krol J, Markiewicz I et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med.15(1), 31–33 (2009).
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med.361(15), 1437–1447 (2009).
   PubMed Web of Science ®Google Scholar
• Aukema TS, Kappers I, Olmos RA et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J. Nucl. Med.51(9), 1344–1348 (2010).
   PubMed Web of Science ®Google Scholar
• Decensi A, Guerrieri-Gonzaga A, Gandini S et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann. Oncol. DOI: 10.1093/annonc/mdq427 (2010) (Epub ahead of print).
   Google Scholar
• Woolston CM, Deen S, Al-Attar A et al. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Free Radic. Biol. Med.49(8), 1263–1272 (2010).
   PubMed Web of Science ®Google Scholar
• Fusi A, Collette S, Busse A et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur. J. Cancer45(18), 3189–3197 (2009).
   PubMedGoogle Scholar
• Vitoux D, Mourah S, Kerob D et al. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases. Arch. Dermatol.145(10), 1105–1113 (2009).
   PubMedGoogle Scholar
• Goto Y, Arigami T, Murali R et al. High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res.23(1), 137–140 (2010).
   PubMedGoogle Scholar
• Hoffmann AC, Wild P, Leicht C et al.MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia12(8), 628–636 (2010).
   PubMed Web of Science ®Google Scholar
• Koyanagi K, Bilchik AJ, Saha S et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin. Cancer Res.14(22), 7391–7396 (2008).
   PubMed Web of Science ®Google Scholar
• Sánchez-Espiridión B, Montalbán C, López A et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood116(8), e12–e17 (2010).
   PubMed Web of Science ®Google Scholar
• Cho WC. Role of miRNAs in lung cancer. Expert Rev. Mol. Diagn.9(8), 773–776 (2009).
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs as therapeutic targets for lung cancer. Expert Opin. Ther. Targets14(10), 1005–1008 (2010).
   PubMed Web of Science ®Google Scholar
• Gallardo E, Navarro A, Viñolas N et al.miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis30(11), 1903–1909 (2009).
   PubMed Web of Science ®Google Scholar
• Cho WC (Ed.). An Omics Perspective on Cancer Research. Springer, Berlin, Germany (2010).
   Google Scholar
• De Giorgi V, Pinzani P, Salvianti F et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J. Invest. Dermatol.130(10), 2440–2447 (2010).
   PubMed Web of Science ®Google Scholar
• Kitago M, Koyanagi K, Nakamura T et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem.55(4), 757–764 (2009).
   PubMed Web of Science ®Google Scholar
• Kojima T, Hashimoto Y, Watanabe Y et al. A simple biological imaging system for detecting viable human circulating tumor cells. J. Clin. Invest.119(10), 3172–3181 (2009).
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Potti A, Delorenzi M et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial. Lancet Oncol.8(12), 1071–1078 (2007).
   PubMed Web of Science ®Google Scholar
• Collingridge D. Expression of concern - validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial. Lancet Oncol.11(9), 813–814 (2010).
   PubMed Web of Science ®Google Scholar